A Phase 2, Sequential, Ascending Dose Study to Character

Project: Research project

Project Details

Description

A Phase 2, Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
StatusFinished
Effective start/end date4/13/104/12/15

Funding

  • Celgene Corporation

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.